A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RDEA3170 Monotherapy in Subjects With Gout

Trial Profile

A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RDEA3170 Monotherapy in Subjects With Gout

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2014

At a glance

  • Drugs Verinurad (Primary)
  • Indications Gout
  • Focus Therapeutic Use
  • Sponsors Ardea Biosciences
  • Most Recent Events

    • 24 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 23 May 2014 Planned End Date changed from 1 May 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record .
    • 26 Feb 2014 Planned End Date changed from 1 Aug 2014 to 1 May 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top